A Phase III, Double-blind, Randomized Placebo-Controlled Study To Evaluate The Effects Of Dalcetrapib On Cardiovascular (CV) Risk In A Genetically Defined Population With A Recent Acute Coronary Syndr

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Madhan Shanmugasundaram
Sponsor
Dalcor Pharmaceuticals (Canada)
Unit
Sarver Heart Center